Helping Translate Life Sciences into Products

Kinexum has provided regulatory consulting services for over 20 years!

We use our experience with major agencies worldwide (e.g. FDA, EMA, MHRA) to help you tackle regulatory, nonclinical, CMC, and related challenges throughout development and commercialization. 

Recent and Upcoming Events

Wow! or Yeow?! 2026

We have published the video for our 9th annual Wow! or Yeow?!, held on January 30, 2026.

Our panel of regulators, policymakers, legal experts, and investors — including Dr. Peter Stein (former Director of CDER OND) — looked back at FDA 2025 and discussed what’s coming next for drugs, biologics, medical devices, digital health, and food products.

A Proposal to Define the End of a Hypoglycemic Event More Precisely

Kinexum’s Dr. Douglas Muchmore calls for a standard definition of the end of a Level 2 hypoglycemic event based on data from continuous glucose monitoring.

To learn more, read “Hypoglycemia Assessed by Continuous Glucose Monitoring: A Proposal to Define the End of a Hypoglycemic Event More Precisely” by Dr. Muchmore, Dr. Peter Calhoun, and Dr. Lutz Heinneman.

News of Interest

FDA Approves Novocure’s First-of-Its-Kind Device to Treat Pancreatic Cancer – read more

Areas of Expertise

Since 2003, Kinexum has supported over 500 companies across the globe.

Our team includes more than seventy subject matter experts, most of whom have MDs, PhDs, MBAs, or JDs. These experts have cumulative decades of experience in regulatory agencies, industry, and academia. We are are based across North America, Europe, and Asia, giving us insight into major markets worldwide.

Kinexum offers regulatory consulting services in strategy and compliance, (including corporate strategy), due diligence, FDA special designations, nonclinical work, CMC, quality assurance and control, rescue, and litigation.

Since 2003, Kinexum has supported approximately 500 companies throughout the world. We have expertise in most therapeutic areas, including but not limited to:

  • Endocrine 
  • Metabolic 
  • Cardiovascular  
  • Gastrointestinal  
  • Cancer 
  • Immunologic
  • Neurologic 
  • Dermatologic 
  • Ophthalmologic 
  • Wound healing 
  • COVID-19 

We work with a broad range of modalities, including but not limited to: 

  • Small molecules 
  • Peptides 
  • Biologics 
  • Cell and gene therapies 
  • Devices, diagnostics, and digital health 
  • Nutritional supplements 
  • Botanicals 

Our Reviews

Why Kinexum?

Passion

We are development geeks, passionate about the translation and development of life science products for unmet medical needs. 

Extension of your team

We are more than external consultants: we advise you as if we were part of your organization, using our expertise to meet your goals.

Team Approach

We take a team approach, carefully assembling a group of subject matter experts to best represent your interests at every stage of development.

Experience

Our consultants typically have decades of experience dealing with regulatory authorities in major markets worldwide, at both the pre-clinical and clinical stages, and across a broad set of therapeutic areas and modalities. 

Client-Centricity

Our experts have hired and fired hundreds of consultants throughout their careers, so we know what turns on and turns off our clients. We don’t up-sell or cross-sell; our focus is the best interest of the client and project. 

REPUTATION

While we are consulting generalists, we also have a reputation as thought leaders in metabolic disease and longevity. Our Kitalys Institute has a track record of pro bono activities, including Targeting Healthy Longevity and the THRIVE Act.